Lechleiter: R&D breakthroughs on the horizon

01/28/2013 | Forbes

The push for personalized medicine, an emphasis on scientific advances and flourishing research into rare diseases suggest that the U.S. biopharmaceutical industry could be on the brink of a renaissance in drug research and development, writes Eli Lilly and Co. CEO John Lechleiter, who serves as chairman of PhRMA. An all-time high number of new drugs are in human testing, and more drugs are being developed for diseases without approved therapies in the past 10 years, Lechleiter writes.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC